MA51029A - Nouveau fragment fab d'anticorps anti-ceacam5 humain - Google Patents
Nouveau fragment fab d'anticorps anti-ceacam5 humainInfo
- Publication number
- MA51029A MA51029A MA051029A MA51029A MA51029A MA 51029 A MA51029 A MA 51029A MA 051029 A MA051029 A MA 051029A MA 51029 A MA51029 A MA 51029A MA 51029 A MA51029 A MA 51029A
- Authority
- MA
- Morocco
- Prior art keywords
- fab fragment
- human ceacam5
- ceacam5 antibodies
- new fab
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1048—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell determinant being a carcino embryonic antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/13—Labelling of peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017133698 | 2017-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA51029A true MA51029A (fr) | 2021-03-24 |
Family
ID=64950161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA051029A MA51029A (fr) | 2017-07-07 | 2018-07-06 | Nouveau fragment fab d'anticorps anti-ceacam5 humain |
Country Status (18)
Country | Link |
---|---|
US (1) | US11667724B2 (fr) |
EP (1) | EP3650470A4 (fr) |
JP (1) | JP7080002B2 (fr) |
KR (1) | KR102665275B1 (fr) |
CN (1) | CN110831977B (fr) |
AU (1) | AU2018296644A1 (fr) |
BR (1) | BR112020000274A2 (fr) |
CA (1) | CA3068691A1 (fr) |
CO (1) | CO2020000517A2 (fr) |
IL (1) | IL271701A (fr) |
JO (1) | JOP20200002A1 (fr) |
MA (1) | MA51029A (fr) |
PH (1) | PH12020500058A1 (fr) |
SG (1) | SG11202000069XA (fr) |
TW (1) | TWI795415B (fr) |
UA (1) | UA126921C2 (fr) |
WO (1) | WO2019009388A1 (fr) |
ZA (1) | ZA202000219B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
WO2020075746A1 (fr) * | 2018-10-10 | 2020-04-16 | アステラス製薬株式会社 | Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué |
US20220242968A1 (en) * | 2019-06-04 | 2022-08-04 | Biotheus Inc. | Anti-CEACAM5 monoclonal antibody and preparation method thereof and use thereof |
KR20230051677A (ko) | 2020-08-20 | 2023-04-18 | 에이투 바이오쎄라퓨틱스, 인크. | 메소텔린 양성 암을 치료하기 위한 조성물 및 방법 |
EP4097486A4 (fr) | 2020-08-20 | 2023-09-06 | A2 Biotherapeutics, Inc. | Compositions et méthodes de traitement de cancers positifs à ceacam |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
WO2000066160A1 (fr) | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Composition medicamenteuse parenterale a fragment d'anticorps monoclonal humanise et procede de stabilisation |
AU4976001A (en) | 2000-03-30 | 2001-10-15 | Dyax Corp | Mucin-1 specific binding members and methods of use thereof |
DE10303664A1 (de) | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US7273608B2 (en) | 2004-03-11 | 2007-09-25 | City Of Hope | Humanized anti-CEA T84.66 antibody and uses thereof |
US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
KR101566393B1 (ko) | 2005-08-03 | 2015-11-05 | 이뮤노젠 아이엔씨 | 면역접합체 제형 |
CA2626082C (fr) | 2005-10-13 | 2017-04-11 | Human Genome Sciences, Inc. | Procedes et compositions destinees au traitement de patients atteints de maladies positives pour des auto-anticorps |
JP2010505775A (ja) | 2006-10-04 | 2010-02-25 | クーベンハヴンス・ユニヴェルシテット | Muc1に対する癌特異的な免疫反応の産生及び癌特異的muc1抗体 |
CA2741798A1 (fr) | 2008-10-28 | 2010-05-06 | Shionogi & Co., Ltd. | Anticorps anti-muc1 |
EP2196476A1 (fr) | 2008-12-10 | 2010-06-16 | Novartis Ag | Formulation d'anticorps |
CN101607985B (zh) * | 2008-12-24 | 2013-03-27 | 中国科学院生物物理研究所 | 抗人cea的单克隆抗体,包含其的组合物,及其用途 |
US8877157B2 (en) | 2009-07-08 | 2014-11-04 | Lantheus Medical Imaging, Inc. | N-alkoxyamide conjugates as imaging agents |
EP2281844A1 (fr) | 2009-07-31 | 2011-02-09 | Glycotope GmbH | Anticorps MUC 1 |
CA2774260C (fr) * | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Anticorps anti-cea de classe i et leurs utilisations |
IN2012DN01981A (fr) | 2009-09-24 | 2015-07-24 | Gene Techno Science Co Ltd | |
EP2347769A1 (fr) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Marqueurs de cellules souches de cancer et utilisations associées |
WO2011135869A1 (fr) | 2010-04-28 | 2011-11-03 | 塩野義製薬株式会社 | Nouvel anticorps muc1 |
CN101928347B (zh) * | 2010-05-05 | 2013-03-27 | 上海海抗中医药科技发展有限公司 | 抗癌胚抗原抗体及其应用 |
JP6061853B2 (ja) | 2010-07-30 | 2017-01-18 | メディミューン,エルエルシー | 活性ポリペプチドまたは免疫複合体の精製方法 |
EA029300B1 (ru) | 2011-03-02 | 2018-03-30 | Роше Гликарт Аг | Антитело к связанному с мембраной человеческому карциноэмбриональному антигену, его получение и применение |
JP6164556B2 (ja) | 2011-12-01 | 2017-07-19 | 国立大学法人 千葉大学 | 非特異的腎集積が低減された放射性標識ポリペプチド作製用薬剤 |
SI3199552T1 (sl) | 2012-11-20 | 2020-06-30 | Sanofi | Protitelesa proti-CEACAM5 in njihove uporabe |
ES2673583T3 (es) | 2013-02-28 | 2018-06-22 | National Cancer Center | Anticuerpo contra fibrina insoluble |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
KR20160054501A (ko) | 2013-08-26 | 2016-05-16 | 맵백스 테라퓨틱스, 인코포레이티드 | 시알릴-루이스 a에 대한 사람 항체 코드화 핵산 |
TWI541022B (zh) | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體-3(fgfr3)之化合物及治療方法 |
CA2942150A1 (fr) | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Formulations stables pour des anticorps anti-cd19 et conjugues anticorps-medicament |
JP6476170B2 (ja) | 2014-04-28 | 2019-03-06 | 医化学創薬株式会社 | 抗muc1抗体又はその抗原結合性断片及びその用途 |
TWI705827B (zh) | 2014-11-07 | 2020-10-01 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
CA2976089A1 (fr) | 2015-02-10 | 2016-08-18 | Minerva Biotechnologies Corporation | Anticorps anti-muc1* humanises |
EP3424940A4 (fr) | 2016-03-01 | 2019-10-30 | National University Corporation Chiba University | Médicament radiomarqué |
BR112019010064A2 (pt) | 2016-11-18 | 2019-10-01 | Astellas Pharma Inc | novo fragmento fab do anticorpo muc1 anti-humano |
US10758632B2 (en) | 2017-02-06 | 2020-09-01 | City Of Hope | NIR-conjugated tumor-specific antibodies and uses thereof |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
KR20200056979A (ko) | 2017-09-26 | 2020-05-25 | 고쿠리츠 다이가쿠 호우징 지바 다이가쿠 | 방사성 약제 |
US20210340276A1 (en) | 2018-05-17 | 2021-11-04 | Astellas Pharma Inc. | Complex having anti-human muc1 antibody fab fragment, peptide linker and/or ligand |
WO2020075746A1 (fr) | 2018-10-10 | 2020-04-16 | アステラス製薬株式会社 | Composition pharmaceutique contenant un complexe de fragment fab d'anticorps au site anti-humain marqué |
AU2020205851A1 (en) | 2019-01-07 | 2021-08-12 | Astellas Pharma Inc. | Conjugate comprising ligand, spacer, peptide linker, and biomolecule |
-
2018
- 2018-07-05 TW TW107123231A patent/TWI795415B/zh active
- 2018-07-06 SG SG11202000069XA patent/SG11202000069XA/en unknown
- 2018-07-06 EP EP18827622.4A patent/EP3650470A4/fr active Pending
- 2018-07-06 US US16/628,975 patent/US11667724B2/en active Active
- 2018-07-06 KR KR1020197035209A patent/KR102665275B1/ko active IP Right Grant
- 2018-07-06 JO JOP/2020/0002A patent/JOP20200002A1/ar unknown
- 2018-07-06 AU AU2018296644A patent/AU2018296644A1/en active Pending
- 2018-07-06 CN CN201880044520.9A patent/CN110831977B/zh active Active
- 2018-07-06 UA UAA202000714A patent/UA126921C2/uk unknown
- 2018-07-06 BR BR112020000274-7A patent/BR112020000274A2/pt unknown
- 2018-07-06 JP JP2019527977A patent/JP7080002B2/ja active Active
- 2018-07-06 CA CA3068691A patent/CA3068691A1/fr active Pending
- 2018-07-06 WO PCT/JP2018/025618 patent/WO2019009388A1/fr unknown
- 2018-07-06 MA MA051029A patent/MA51029A/fr unknown
-
2019
- 2019-12-25 IL IL271701A patent/IL271701A/en unknown
-
2020
- 2020-01-07 PH PH12020500058A patent/PH12020500058A1/en unknown
- 2020-01-13 ZA ZA2020/00219A patent/ZA202000219B/en unknown
- 2020-01-17 CO CONC2020/0000517A patent/CO2020000517A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AU2018296644A1 (en) | 2020-01-23 |
JOP20200002A1 (ar) | 2020-01-06 |
TW201920273A (zh) | 2019-06-01 |
CN110831977B (zh) | 2023-06-09 |
ZA202000219B (en) | 2021-08-25 |
JPWO2019009388A1 (ja) | 2020-05-07 |
CN110831977A (zh) | 2020-02-21 |
JP7080002B2 (ja) | 2022-06-03 |
KR102665275B1 (ko) | 2024-05-13 |
EP3650470A4 (fr) | 2021-03-24 |
UA126921C2 (uk) | 2023-02-22 |
TWI795415B (zh) | 2023-03-11 |
SG11202000069XA (en) | 2020-02-27 |
WO2019009388A1 (fr) | 2019-01-10 |
RU2020105654A (ru) | 2021-08-09 |
US11667724B2 (en) | 2023-06-06 |
EP3650470A1 (fr) | 2020-05-13 |
KR20200026185A (ko) | 2020-03-10 |
CO2020000517A2 (es) | 2020-01-31 |
PH12020500058A1 (en) | 2020-09-28 |
RU2020105654A3 (fr) | 2021-10-29 |
IL271701A (en) | 2020-02-27 |
BR112020000274A2 (pt) | 2020-07-14 |
CA3068691A1 (fr) | 2019-01-10 |
US20200123270A1 (en) | 2020-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA51029A (fr) | Nouveau fragment fab d'anticorps anti-ceacam5 humain | |
MA52742A (fr) | Anticorps bispécifiques dll3-cd3 | |
MA46851A (fr) | NOUVEAU FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAIN | |
MA55043A (fr) | Anticorps hétérodimériques se liant à l'antigène cd3 et l'antigène cd20 | |
MA53434A (fr) | Anticorps anti-tigit | |
MA52884A (fr) | Anticorps anti-il-11 | |
DK3389699T3 (da) | Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA50505A (fr) | Anticorps 2 + 1 bispécifiques (contorsbodies) | |
MA42924A (fr) | Variants optimisés d'anticorps anti-vegf | |
MA55347A (fr) | Anticorps anti-lag3 et fragments de fixation à l'antigène | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA55063A (fr) | Anticorps humanisés cd19 antihumains et procédés d'utilisation | |
MA55868A (fr) | Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation | |
DK3883966T3 (da) | Humaniseret anti-human-pd-1-antistof | |
MA52366A (fr) | Anticorps anti-tl1a optimisés | |
ZA201701920B (en) | Anti-human il-17 monoclonal antibodies and use thereof | |
MA52212A (fr) | Anticorps multivalent | |
MA52152A (fr) | Anticorps | |
MA53905A (fr) | Anticorps stabilisant trem2 | |
SG11202103670XA (en) | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex | |
MA51902A (fr) | Schémas posologiques d'anticorps b7-h4 | |
MA53322A (fr) | Anticorps procoagulants améliorés | |
MA44777A (fr) | Anticorps humanisés anti-basigine et leur utilisation | |
IL281608A (en) | Antibodies against human CD45RC and their use |